Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

JPMorgan Chase & Co. Gives Kestra Medical Technologies Weighty Rating

Guavy AI Editorial Team
Instruments
JPM
Share

Kestra Medical Technologies (NASDAQ:KMTS) has received coverage from JPMorgan Chase & Co. in a research report issued on Monday, according to Benzinga.

The firm set an 'overweight' rating and a $30.00 price target on the stock, suggesting a potential upside of 13.64% from its current price.

This is not the first time Kestra Medical Technologies has received analyst attention; several other firms have also weighed in with their views on the company's stock.

More on Stocks

Stocks 1m ago

Apple's 20th Anniversary iPhone Design Reportedly Cancelled

Stocks 1m ago

Apple Stock Falls as Analyst Downgrades and Supply-Chain Concerns Bite

Stocks 2m ago

Apple Boosts Dividend for 15th Consecutive Year Ahead of Leadership Handover

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy